Key facts
- MapLight Therapeutics (NAS: MPLT)’s last known valuation is $704.3M (Oct 2025).
- It has raised $919.4M; the latest was PIPE ($8.1M) in Oct 2025.
- Notable investors include Novo Holdings, The Goldman Sachs Group.
- 1 institutional filer reports fund marks on MapLight Therapeutics (NAS: MPLT) across 1 filings.
- Status: Publicly Held.
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for MapLight Therapeutics (NAS: MPLT)
- ·The full record, as it builds
Funding rounds
No funding rounds for MapLight Therapeutics (NAS: MPLT) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About MapLight Therapeutics (NAS: MPLT)
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.
- Sector
- Healthcare
- HQ
- Burlington, MA, United States
- Founded
- 2018
- Employees
- 133
- Website
- maplightrx.com/
- Ownership
- Publicly Held
MapLight Therapeutics (NAS: MPLT) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MapLight Therapeutics (NAS: MPLT) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
1 filers · latest Apr 20261 SEC-registered fund reported 1 fair-value mark on MapLight Therapeutics (NAS: MPLT) between Apr 2026 and Apr 2026. Filer-level marks and implied $/share are available to Pro members.